An overview of modern embolic protection in percutaneous coronary intervention.

Coronary embolism due to atherosclerotic debris is a rather common cause of post-procedural complications. While evidence has shown that both arteriolar vasodilators and platelet glycoprotein inhibitors have proven ineffective against post- and peri-procedural embolism,5 mechanical interventional devices have been shown to improve (lower) 30-day MACE rates. These interventions include distal filtration, distal, and proximal occlusion balloons. The distal occlusion balloon was the first approach to embolic protection. The intervention involves placement of a low pressure (<2 atm) balloon distal to the lesion of interest. Antegrade flow is temporarily interrupted while the lesion is treated. Mounted on conventional 0.014-inch guidewire shafts, distal filtration systems follow a similar intervention method to distal occlusion. In this proceeding, a delivery/recovery sheath catheter deploys an expandable filter device approximating the lumen, which is later removed following PTCA or stent placement in retroversion. The variety of existing, rather novel filter designs typically feature a wire mounted umbrella-type filter consisting of laser-drilled micropores design varied, averaging approximately 100 microm. The primary benefit derived of distal filtration includes the trivial uninterruption of antegrade flow. Unlike distal occlusion, proximal devices allow for vessel protection before lesion crossing, a great advantage in cases involving thrombosis, vulnerable plaque, or primary unstable angina. Proximal occlusion follows a nearly identical implementation as distal occlusion. While substantial research is still needed, interventionalists are advised to always use embolic protection devices in SVG interventions.

Effect of five-membered heterocycles against Leishmania donovani infection.

Impact of change of heteroatom in pentavalent heterocycles, viz., pyrroles, isoxazoles, imidazoles and crotonates on the profile of antileishmanial activity against amastigotes of L. donovani using in vivo test system and macrophage-amastigote culture system has been studied. Sixty-three compounds were tested. Nine imidazoles showed marginal activity in vivo, whereas 3 out of 10 compounds of isoxazolone series and 2 out of 4 substituted aminocrotonates exhibited antileishmanial activity. Of the 30 substituted pyrroles, except 8 all showed antileishmanial activity in vivo on day 7 post treatment.

Exploration of antileishmanial activity in heterocycles; results of their in vivo & in vitro bioevaluations.

A total of 51 imidazoles, pyrroles, quinolines and isoxazolines compounds were screened for antileishmanial activity in vivo and in vitro, using Leishmania donovani as the test parasite. The screening revealed hitherto unknown antileishmanial activity in these heterocycles. Three of the compounds screened (one belonging to isoxazoline series and two from pyrrole series) showed significant anti-leishmanial activity, ranging from 86-91 per cent inhibition in hamsters. When tested in vitro, using macrophage amastigote culture system, these compounds showed inhibition of 62-78 per cent at 30 micrograms/ml concentration.